Abstract:Background Pregnancy leads to physiological changes within the cardiovascular system such as increased plasma volume and cardiac output or hypercoagulability. These changes can be challenging for women with pre-existing cardiovascular disease with higher risks of complications. The guidelines of the European Society of Cardiology recommend treating high-risk patients in specialized centres by an interdisciplinary pregnancy heart team. In a team-based approach, the Pregnancy Heart Team was founded at our university hospital, in order to establish specific structures of communication and responsibility. Methods A prospective registry of all patients treated by the Pregnancy Heart Team between November 2022 and March 2024 was established. Patients consisted of women with pre-existing cardiovascular disease undergoing pregnancy as well as women who developed pregnancy-associated cardiovascular disease. Patients were evaluated throughout pregnancy by lab work and echocardiography during each trimester as well as in the postpartum period. Results In total 39 women (mean age 34±5 years) were prospectively included in the registry. 17 patients (43.5%) were classified as mWHO ≥ III. 17 patients (43.5 %) with pre-existing (pregnancy-associated) cardiovascular disease were managed throughout pregnancy and delivery. 9 patients (18.4 %) developed pregnancy-associated cardiovascular diseases such as peripartum cardiomyopathy or spontaneous coronary artery dissection. Preliminary data shows that mean left-ventricular ejection fraction remained stable during pregnancy with a non-significant trend towards lower values postpartum. Cardiac biomarkers such as high-sensitivity troponin T and NT-pro-BNP showed a non-significant trend towards increased values in the third trimester and postpartum. Adverse maternal outcomes occurred in 14 patients (35.9 %), including preterm premature rupture of membranes (12.2%), gestational hypertension (7.6%), gestational diabetes (5.1%), preeclampsia/eclampsia (7.6%) and delivery-associated complications (10.2%). Fetal complications included macrosomia (10.2%) or intrauterine growth retardation (5.1%). Discussion These preliminary data of a real-world patient collectivedemonstrate that a significant number of patients experienced adverse pregnancy outcomes which was associated with a trend towards increased cardiac biomarkers throughout pregnancy and postpartum. As recent studies have shown, interpretation of standard parameters such as cardiac biomarkers is not fully understood during pregnancy, especially in women with pre-existing cardiovascular disease. Our data may aid to understand prognostic implications of cardiac biomarkers during pregnancy.

Cardiac function in pregnant women with preeclampsia

Maternal circulatory levels of procalcitonin, uric acid, and lipid profile in Early-onset preeclampsia and Late-onset preeclampsia

[Clinical Analysis of Cardiac Reserve Function and Outcome of Preeclampsia.].

Association of Perinatal Cardiovascular Features with Angiotensin System Expressions in Maternal Preeclampsia

Acute Cardiac Effects of Severe Pre-Eclampsia

Coronary Microvascular Function Following Severe Preeclampsia

Intrapartum trends of NT-proBNP and hs-cTnT in patients with severe features of preeclampsia

Changes of coagulation function and platelet parameters in preeclampsia and their correlation with pregnancy outcomes

Changes in expression levels of immune cells and inflammatory cytokines in pre-eclampsia patients before and after delivery

The Immediate and Long-Term Impact of Preeclampsia on Offspring Vascular and Cardiac Physiology in the Preterm Infant

Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia

Cardiac Structure and Function in 8- to 12-Year-Old Children Following In-Utero Exposure to Preeclampsia (FINNCARE Study)

Left Ventricular Hypertrophy in Women With a History of Preeclampsia

Decreased postpartum exercise capacity after a diagnosis of pre-eclampsia: Implications for CVD risk prediction

Cardiovascular health of women 10 to 20 years after placenta-related pregnancy diseases considering the possible effect of pentaerythrityl tetranitrate treatment during pregnancy on long-term maternal cardiovascular health (PAVA study)

Analysis of perinatal coagulation function in preeclampsia

Fibrinolytic Changes in Women with Preeclampsia

Effect of Maternal Preeclampsia on Cardiac Structure and Function in Very Low Birth Weight Infants

Preliminary data on short-term outcomes within the cardio-obstetrics registry

Blood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia